Literature DB >> 25974248

Structural diversity of the epigenetics pocketome.

Alexandre Cabaye1, Kong T Nguyen1, Lihua Liu1, Vineet Pande2, Matthieu Schapira1,3.   

Abstract

Protein families involved in chromatin-templated events are emerging as novel target classes in oncology and other disease areas. The ability to discover selective inhibitors against chromatin factors depends on the presence of structural features that are unique to the targeted sites. To evaluate challenges and opportunities toward the development of selective inhibitors, we calculated all pair wise structural distances between 575 structures from the protein databank representing 163 unique binding pockets found in protein domains that write, read or erase post-translational modifications on histones, DNA, and RNA. We find that the structural similarity of binding sites does not always follow the sequence similarity of protein domains. Our analysis reveals increased risks of activity across target-class for compounds competing with the cofactor of protein arginine methyltransferases, lysine acetyltransferases, and sirtuins, while exploiting the conformational plasticity of a protein target is a path toward selective inhibition. The structural diversity landscape of the epigenetics pocketome can be explored via an open-access graphic user interface at thesgc.org/epigenetics_pocketome.
© 2015 Wiley Periodicals, Inc.

Keywords:  binding pocket; chromatin factors; drug design; epigenetics; inhibitor; pocketome; selectivity; structure

Mesh:

Substances:

Year:  2015        PMID: 25974248     DOI: 10.1002/prot.24830

Source DB:  PubMed          Journal:  Proteins        ISSN: 0887-3585


  3 in total

1.  Flavonoids as Putative Epi-Modulators: Insight into Their Binding Mode with BRD4 Bromodomains Using Molecular Docking and Dynamics.

Authors:  Fernando D Prieto-Martínez; José L Medina-Franco
Journal:  Biomolecules       Date:  2018-07-23

2.  Novel pharmacological maps of protein lysine methyltransferases: key for target deorphanization.

Authors:  Obdulia Rabal; Andrea Castellar; Julen Oyarzabal
Journal:  J Cheminform       Date:  2018-07-21       Impact factor: 5.514

Review 3.  The timeline of epigenetic drug discovery: from reality to dreams.

Authors:  A Ganesan; Paola B Arimondo; Marianne G Rots; Carmen Jeronimo; María Berdasco
Journal:  Clin Epigenetics       Date:  2019-12-02       Impact factor: 6.551

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.